Evidence map›Paper›PMID 17410435›Full record

Trial reportDigestive diseases and sciences2007

Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up.

Giuseppe Comparato, Libera Fanigliulo, Lucas G Cavallaro, Giovanni Aragona, Giulia Martina Cavestro, Veronica Iori, Marta Maino, Giancarlo Mazzocchi, Pierantonio Muzzetto, Giancarlo Colla and 3 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Digestive diseases and sciences, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Mesalamine (5-ASA) for the prevention of recurrent diverticulitis.The Cochrane database of systematic reviews · 2017
    Pooled it
  5. Guideline
  6. Systematic review of medical therapy to prevent recurrent diverticulitis.International journal of colorectal disease · 2012
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Management of diverticular disease.Nature reviews. Gastroenterology & hepatology · 2015
    Review
  18. Article
  19. Diverticular disease is associated with increased risk of subsequent arterial and venous thromboembolic events.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2014
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giuseppe ComparatoDepartment of Clinical Sciences, Chair of Gastroenterology, University of Parma, Parma, Italy.
Libera Fanigliulo
Lucas G Cavallaro
Giovanni Aragona
Giulia Martina Cavestro
Veronica Iori
Marta Maino
Giancarlo Mazzocchi
Pierantonio Muzzetto
Giancarlo Colla
Mario Sianesi
Angelo Franzé
Francesco Di Mario

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In uncomplicated diverticular disease, treatment is aimed at relieving symptoms. The aim of the present study was to evaluate the efficacy of mesalazine for symptomatic relief of uncomplicated diverticular disease of the colon. Two hundred sixty-eight consecutive eligible outpatients (122 male, 146 female; age, 66.1 years; range, 31-81 years) were enrolled in four treatment schedules in a randomized fashion: Group R1 (66 patients), rifaximin, 200 mg bid; Group R2 (69 patients), rifaximin, 400 mg bid; Group M1 (67 patients), mesalazine, 400 mg bid; and Group M2 (66 patients), mesalazine, 800 mg bid. Treatments were administered for 10 days every month for 12 months. Clinical evaluations were performed at admission and at 3-month intervals for 12 months considering 12 clinical variables (upper and lower abdominal pain/discomfort, tenesmus, diarrhea, abdominal tenderness, fever, bloating, general illness, nausea, emesis, dysuria, bleeding) graded as 0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe. The Global Symptomatic Score (GSS) was calculated using the sum of each symptom score. Two hundred forty-four patients completed the 12- month study; 24 were discontinued (14 treated with rifaximin and 10 treated with mesalazine) either as voluntary dropouts or because they developed side effects and/or complications. Group M2 demonstrated a lower frequency of many symptoms after 6 and 12 months of treatment; the mean GSS was significantly lower in Group M2 after 6 and 12 months of therapy by both intention-to-treat and per-protocol analyses. Patients treated with mesalazine (Groups M1+M2) had a lower GSS than subjects treated with rifaximin (Groups R1+R2) during the 12-month follow-up period. We conclude that cyclic administration of mesalazine is effective for symptomatic relief of uncomplicated diverticular disease of the colon. Some symptoms showed greater improvement with mesalazine, 800 mg bid, than with the other treatment schedules.

Indexed as

AdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalBarium SulfateColonoscopyContrast MediaDiverticulitis, ColonicDiverticulosis, ColonicEnemaFemaleFollow-Up StudiesHumansMaleMesalamineMiddle AgedAnti-Inflammatory Agents, Non-SteroidalBarium SulfateContrast MediaMesalamine

Identifiers

PMID17410435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.